Zydus gets permission to initiate the Phase 1 trial of ZYIL1

Zydus gets permission to initiate the Phase 1 trial of ZYIL1

by admin- Monday, December 7th, 2020 04:27:13 PM

Zydus, a leading discovery primarily based, worldwide pharmaceutical business enterprise has received permission to initiate the Phase 1 medical trial of ZYIL1, a novel oral small molecule
NLRP3 inhibitor candidate.

News Updates